New drug trial offers hope before chemotherapy for Tough-to-Treat breast cancer
NCT ID NCT07205822
Summary
This study is testing an investigational drug called Dato-DXd for people with a specific type of advanced breast cancer that has spread and no longer responds to standard hormone treatments. The goal is to see if this drug, given as an IV infusion every 3 weeks, can effectively control the cancer and delay its progression before patients need to start chemotherapy. Researchers will closely monitor how well the treatment works and its safety in about 100 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
WITHDRAWNLargo, Florida, 33770, United States
-
Research Site
RECRUITINGFort Wayne, Indiana, 46825, United States
-
Research Site
RECRUITINGOmaha, Nebraska, 68130, United States
-
Research Site
NOT_YET_RECRUITINGNew York, New York, 10021, United States
-
Research Site
RECRUITINGHouston, Texas, 77024, United States
-
Research Site
RECRUITINGPuyallup, Washington, 98373, United States
-
Research Site
RECRUITINGBeijing, 100021, China
-
Research Site
NOT_YET_RECRUITINGChangsha, 410013, China
-
Research Site
RECRUITINGGuangzhou, 510060, China
-
Research Site
NOT_YET_RECRUITINGLinyi, 276001, China
-
Research Site
NOT_YET_RECRUITINGShandong, 250117, China
-
Research Site
NOT_YET_RECRUITINGWuhan, 430071, China
-
Research Site
NOT_YET_RECRUITINGZhengzhou, 450008, China
-
Research Site
RECRUITINGClermont-Ferrand, 63050, France
-
Research Site
RECRUITINGLa Roche-sur-Yon, 85925, France
-
Research Site
RECRUITINGMontpellier, 34070, France
-
Research Site
NOT_YET_RECRUITINGParis, 75005, France
-
Research Site
RECRUITINGPierre-Bénite, 69310, France
-
Research Site
RECRUITINGAviano, 33081, Italy
-
Research Site
RECRUITINGFlorence, 50134, Italy
-
Research Site
RECRUITINGMeldola, 47014, Italy
-
Research Site
NOT_YET_RECRUITINGMilan, 20141, Italy
-
Research Site
RECRUITINGNaples, 80131, Italy
-
Research Site
NOT_YET_RECRUITINGRoma, 00168, Italy
-
Research Site
RECRUITINGBukgu, 41404, South Korea
-
Research Site
NOT_YET_RECRUITINGGoyang-si, 410-769, South Korea
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 06273, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGSeoul, 06591, South Korea
-
Research Site
RECRUITINGSeoul, 136705, South Korea
-
Research Site
RECRUITINGSeoul, 3722, South Korea
-
Research Site
RECRUITINGSeoul, 5505, South Korea
-
Research Site
NOT_YET_RECRUITINGA Coruña, 15006, Spain
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
NOT_YET_RECRUITINGGranada, 18007, Spain
-
Research Site
NOT_YET_RECRUITINGMadrid, 28033, Spain
-
Research Site
NOT_YET_RECRUITINGMadrid, 28040, Spain
-
Research Site
NOT_YET_RECRUITINGSeville, 41009, Spain
-
Research Site
NOT_YET_RECRUITINGValencia, 46009, Spain
Conditions
Explore the condition pages connected to this study.